Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01356823 | Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine | completed | Phase 2 | 1,600 | Xiamen UniversityOTHER | 1 | Jan 5, 2016 | clinicaltrials |
| NCT00031954 | Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | 105 | AGO Study GroupOTHER | 1 | Dec 23, 2015 | clinicaltrials |
| NCT01624493 |
| BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients |
| withdrawn |
| Phase 1 / Phase 2 |
| 0 |
| Hoosier Cancer Research NetworkOTHER |
| 3 |
| Dec 23, 2015 |
| clinicaltrials |
| NCT00390234 | Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 2 | Dec 7, 2015 | clinicaltrials |
| NCT00660101 | Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer | unknown | Phase 1 / Phase 2 | 34 | AVAX TechnologiesINDUSTRY | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00059787 | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Dec 1, 2015 | clinicaltrials |
| NCT00313612 | Oxaliplatin and Topotecan in Advance Ovarian Cancer | terminated | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Nov 27, 2015 | clinicaltrials |
| NCT00520598 | Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) | completed | Phase 2 | 511 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 26, 2015 | clinicaltrials |
| NCT00024258 | Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | completed | Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2015 | clinicaltrials |
| NCT01091259 | Irinotecan and Bevacizumab for Recurrent Ovarian Cancer | completed | Phase 2 | 29 | NYU Langone HealthOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT00238121 | Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 2 | Nov 20, 2015 | clinicaltrials |
| NCT00057863 | Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2015 | clinicaltrials |
| NCT00275028 | AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Nov 9, 2015 | clinicaltrials |
| NCT00453310 | Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment | completed | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 27, 2015 | clinicaltrials |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 79 | Otsuka Novel Products GmbHINDUSTRY | 1 | Oct 20, 2015 | clinicaltrials |
| NCT02309658 | Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients | completed | Phase 2 | 50 | Professor Fernando Figueira Integral Medicine InstituteOTHER | 1 | Oct 16, 2015 | clinicaltrials |
| NCT00703196 | Folic Acid Clinical Trial for the Prevention of Cervical Cancer | completed | Phase 2 | 368 | University of Alabama at BirminghamOTHER | 1 | Oct 8, 2015 | clinicaltrials |
| NCT00758732 | Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma | terminated | Phase 2 | 34 | Hellenic Oncology Research GroupOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT01026792 | Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery | completed | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2015 | clinicaltrials |
| NCT00318370 | Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy | completed | Phase 2 | 58 | MorphotekINDUSTRY | 2 | Sep 9, 2015 | clinicaltrials |
| NCT01296035 | Panitumumab and Gemcitabine in Relapsed Ovarian Cancer(PanGem) | terminated | Phase 2 | 8 | Women and Infants Hospital of Rhode IslandOTHER | 1 | Aug 25, 2015 | clinicaltrials |
| NCT02039791 | Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer | unknown | Phase 2 | 20 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00945139 | Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA) | completed | Phase 2 | 46 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 31, 2015 | clinicaltrials |
| NCT00421889 | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | completed | Phase 1 / Phase 2 | 80 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00100841 | Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer | completed | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00510250 | A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer | completed | Phase 1 / Phase 2 | 13 | University Health Network, TorontoOTHER | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00072267 | UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | — | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00739830 | Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) | completed | Phase 2 | 130 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 1, 2015 | clinicaltrials |
| NCT01175772 | Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy | terminated | Phase 2 | 6 | HaEmek Medical Center, IsraelOTHER | 1 | Jun 23, 2015 | clinicaltrials |
| NCT00365443 | Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003) | withdrawn | Phase 2 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 19, 2015 | clinicaltrials |
| NCT01880996 | Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Sheba Medical CenterOTHER_GOV | 1 | Jun 11, 2015 | clinicaltrials |
| NCT00096993 | A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 131 | Genentech, Inc.INDUSTRY | 1 | Jun 10, 2015 | clinicaltrials |
| NCT01690598 | Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | completed | Phase 1 / Phase 2 | 22 | Vejle HospitalOTHER | 1 | Jun 10, 2015 | clinicaltrials |
| NCT00260039 | Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001) | completed | Phase 2 | 680 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2015 | clinicaltrials |
| NCT00551187 | A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) | completed | Phase 2 | 620 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2015 | clinicaltrials |
| NCT00217633 | Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer | completed | Phase 2 | 38 | Gynecologic Oncology GroupNETWORK | 2 | May 29, 2015 | clinicaltrials |
| NCT01200797 | SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin | terminated | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT01379534 | A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | completed | Phase 2 | 53 | Novartis PharmaceuticalsINDUSTRY | 7 | May 20, 2015 | clinicaltrials |
| NCT02188550 | Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | unknown | Phase 2 | 20 | Sinai Hospital of BaltimoreOTHER | 1 | May 19, 2015 | clinicaltrials |
| NCT00343044 | Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | completed | Phase 2 | 40 | Benaroya Research InstituteOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT00072566 | Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | May 12, 2015 | clinicaltrials |
| NCT00430781 | Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer | completed | Phase 2 | 228 | GlaxoSmithKlineINDUSTRY | 13 | May 8, 2015 | clinicaltrials |
| NCT02235324 | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT02435186 | p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | unknown | Phase 2 | 100 | Shenzhen SiBiono GeneTech Co.,LtdINDUSTRY | 1 | May 6, 2015 | clinicaltrials |
| NCT00303823 | Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia | completed | Phase 2 | 98 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT01196741 | Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer(SaPPrOC) | completed | Phase 2 / Phase 3 | 107 | University College, LondonOTHER | 1 | May 5, 2015 | clinicaltrials |
| NCT00039585 | Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00267696 | Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00003880 | Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer | terminated | Phase 2 / Phase 3 | 132 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 16, 2015 | clinicaltrials |
| NCT02406365 | Diagnostic Imaging Aid for Management of Cervical Lesions(FFC) | unknown | Phase 2 | 618 | Brookdale University Hospital Medical CenterOTHER | 1 | Apr 10, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Jan 5, 2016source: clinicaltrials